Pharmaceutical

Armed with Phase III win, Incyte eyes label expansion for Monjuvi

The Phase III inMIND trial evaluating Monjuvi as a combination treatment in relapsed/ refractory follicular lymphoma met its primary endpoint.

Aug 17, 2024 - 04:00
Armed with Phase III win, Incyte eyes label expansion for Monjuvi
The Phase III inMIND trial evaluating Monjuvi as a combination treatment in relapsed/ refractory follicular lymphoma met its primary endpoint.
Read the original article

Tags:

Previous Article

Bavarian Nordic seeks authorisation for mpox vaccine’s use in adolescents

Next Article

Lykos cuts team by 75%, vows to keep MDMA program despite FDA veto

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Novartis’ urticaria drug meets all endpoints in Phase III trials

Novartis’ urticaria drug meets all endpoints in Phase I...

Nov 12, 2023

Israeli company bags $4.2m contract to develop cell therapy for radiation poisoning

Israeli company bags $4.2m contract to develop cell the...

Jul 11, 2023

US lawmakers urge administration to take action against Wuxi

US lawmakers urge administration to take action against...

Feb 14, 2024